Product Code: VMR11218912
The global demand for Artificial Intelligence in Genomics Market is presumed to reach the market size of nearly USD 11.22 BN by 2030 from USD 1.13 BN in 2022 with a CAGR of 33.3% under the study period 2023 - 2030.
Artificial Intelligence in Genomics involves the utilization of machine learning in the field of healthcare to diagnose and understand genetic disorders. AI in genomics helps healthcare professionals to understand better deadly diseases like cancer and several rare and degenerative conditions in patients. AI helps in the structuring of genomic data, and this helps a great deal in interpreting diseases faster than doing it through human intervention. It enables a faster analysis of the structure, functioning and development of the genetic materials.
MARKET DYNAMICS:
Artificial Intelligence in Genomics market shows a satisfactory growth rate during the projection period. The role of genomics in personalized medicine will help the growth of this market as the application of AI helps in the faster manufacturing of medicines. The necessity to reduce time and cost in drug development and increase investments made in AI in genomics by the public and private sector organizations have contributed to the market's growth. Moreover, the growing manufacturing of precision medicine, which focuses on the role of genetics, lifestyle, and environment in the diseases in humans, is another market driver of growth. Similarly, the personalized medicine method that uses patients' genetic profiles to discover the individual patient requirements before prescribing medicine is likely to influence the growth of the AI in genomics market.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of artificial intelligence in genomics. The growth and trends of artificial intelligence in genomics industry provide a holistic approach to this study.
MARKET SEGMENTATION:
This section of the artificial intelligence in genomics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Offering
By Technology
- Machine Learning
- Deep Learning
- Supervised Learning
- Reinforcement Learning
- Unsupervised Learning
- Other Machine Learning Technologies
- Other Technologies
By Functionality
- Genome Sequencing
- Gene Editing
- Clinical Workflows
- Predictive Genetic Testing & Preventive Medicine
By Application
- Diagnostics
- Drug Discovery & Development
- Precision Medicine
- Agriculture & Animal Research
- Other Applications
By End User
- Pharmaceutical & Biotech Companies
- Healthcare Providers
- Research Centers, Academic Institutes
- Government Organizations
- Other End Users
REGIONAL ANALYSIS:
This section covers the regional outlook, which accentuates current and future demand for the Artificial Intelligence in Genomics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the artificial intelligence in genomics market include IBM (US), Microsoft (US), NVIDIA Corporation (US), Deep Genomics (Canada), BenevolentAI (UK), Fabric Genomics Inc. (US), Verge Genomics (US), Freenome Holdings, Inc. (US), MolecularMatch Inc. (US), Cambridge Cancer Genomics (UK), SOPHiA GENETICS (US), Data4Cure Inc. (US), PrecisionLife Ltd (UK), Genoox Ltd. (US), Lifebit (UK), Diploid (Belgium), FDNA Inc. (US), DNAnexus Inc. (US), Empiric Logic (Ireland), and Engine Biosciences Pte. Ltd. (US). This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
TABLE OF CONTENTS
1 . PREFACE
- 1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
- 2.1. Highlights of Market
- 2.2. Global Market Snapshot
3 . ARTIFICIAL INTELLIGENCE IN GENOMICS - INDUSTRY ANALYSIS
- 3.1. Introduction - Market Dynamics
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Opportunities
- 3.5. Industry Trends
- 3.6. Porter's Five Force Analysis
- 3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Offering
- 3.7.2 Market Attractiveness Analysis By Technology
- 3.7.3 Market Attractiveness Analysis By Functionality
- 3.7.4 Market Attractiveness Analysis By Application
- 3.7.5 Market Attractiveness Analysis By End User
- 3.7.6 Market Attractiveness Analysis By Region
4 . VALUE CHAIN ANALYSIS
- 4.1. Value Chain Analysis
- 4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
- 4.3. List of Potential Buyers
- 4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend
5 IMPACT ANALYSIS OF COVID-19 OUTBREAK
- 5.1. Impact Analysis of Covid-19 Outbreak
- 5.1.1. Direct Impact on Production
- 5.1.2. Supply Chain and Market Disruption
- 5.1.3. Financial Impact on Firms and Financial Markets
- 5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
- 5.3. Market: Pre V/S Post COVID-19
- 5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic
- 5.5. COVID-19: Micro and Macro Factor Analysis
6 . GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET ANALYSIS BY OFFERING
- 6.1 Overview by Offering
- 6.2 Historical and Forecast Data
- 6.3 Analysis by Offering
- 6.4 Software Historic and Forecast Sales by Regions
- 6.5 Services Historic and Forecast Sales by Regions
7 . GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET ANALYSIS BY TECHNOLOGY
- 7.1 Overview by Technology
- 7.2 Historical and Forecast Data
- 7.3 Analysis by Technology
- 7.4 Machine Learning Historic and Forecast Sales by Regions
- 7.5 Deep Learning Historic and Forecast Sales by Regions
- 7.6 Supervised Learning Historic and Forecast Sales by Regions
- 7.7 Reinforcement Learning Historic and Forecast Sales by Regions
- 7.8 Unsupervised Learning Historic and Forecast Sales by Regions
- 7.9 Other Machine Learning Technologies Historic and Forecast Sales by Regions
- 7.10. Other Technologies Historic and Forecast Sales by Regions
8 . GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET ANALYSIS BY FUNCTIONALITY
- 8.1 Overview by Functionality
- 8.2 Historical and Forecast Data
- 8.3 Analysis by Functionality
- 8.4 Genome Sequencing Historic and Forecast Sales by Regions
- 8.5 Gene Editing Historic and Forecast Sales by Regions
- 8.6 Clinical Workflows Historic and Forecast Sales by Regions
- 8.7 Predictive Genetic Testing & Preventive Medicine Historic and Forecast Sales by Regions
9 . GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET ANALYSIS BY APPLICATION
- 9.1 Overview by Application
- 9.2 Historical and Forecast Data
- 9.3 Analysis by Application
- 9.4 Diagnostics Historic and Forecast Sales by Regions
- 9.5 Drug Discovery & Development Historic and Forecast Sales by Regions
- 9.6 Precision Medicine Historic and Forecast Sales by Regions
- 9.7 Agriculture & Animal Research Historic and Forecast Sales by Regions
- 9.8 Other Applications Historic and Forecast Sales by Regions
10 . GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET ANALYSIS BY END USER
- 10.1 Overview by End User
- 10.2 Historical and Forecast Data
- 10.3 Analysis by End User
- 10.4 Pharmaceutical & Biotech Companies Historic and Forecast Sales by Regions
- 10.5 Healthcare Providers Historic and Forecast Sales by Regions
- 10.6 Research Centers, Academic Institutes Historic and Forecast Sales by Regions
- 10.7 Government Organizations Historic and Forecast Sales by Regions
- 10.8 Other End Users Historic and Forecast Sales by Regions
11 . GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET ANALYSIS BY GEOGRAPHY
- 11.1. Top Company Share Analysis
- 11.2. Introduction
- 11.3. North America Sales Analysis
- 11.3.1. Overview, Historic and Forecast Sales Analysis
- 11.3.2. North America By Segment Sales Analysis
- 11.3.3. North America By Country Sales Analysis
- 11.3.4. United State Sales Analysis
- 11.3.5. Canada Sales Analysis
- 11.3.6. Mexico Sales Analysis
- 11.4. Europe Sales Analysis
- 11.4.1. Overview, Historic and Forecast Sales Analysis
- 11.4.2. Europe by Segment Sales Analysis
- 11.4.3. Europe by Country Sales Analysis
- 11.4.4. United Kingdom Sales Analysis
- 11.4.5. France Sales Analysis
- 11.4.6. Germany Sales Analysis
- 11.4.7. Italy Sales Analysis
- 11.4.8. Russia Sales Analysis
- 11.4.9. Rest Of Europe Sales Analysis
- 11.5. Asia Pacific Sales Analysis
- 11.5.1. Overview, Historic and Forecast Sales Analysis
- 11.5.2. Asia Pacific by Segment Sales Analysis
- 11.5.3. Asia Pacific by Country Sales Analysis
- 11.5.4. China Sales Analysis
- 11.5.5. India Sales Analysis
- 11.5.6. Japan Sales Analysis
- 11.5.7. South Korea Sales Analysis
- 11.5.8. Australia Sales Analysis
- 11.5.9. Rest Of Asia Pacific Sales Analysis
- 11.6. Latin America Sales Analysis
- 11.6.1. Overview, Historic and Forecast Sales Analysis
- 11.6.2. Latin America by Segment Sales Analysis
- 11.6.3. Latin America by Country Sales Analysis
- 11.6.4. Brazil Sales Analysis
- 11.6.5. Argentina Sales Analysis
- 11.6.6. Peru Sales Analysis
- 11.6.7. Chile Sales Analysis
- 11.6.8. Rest of Latin America Sales Analysis
- 11.7. Middle East & Africa Sales Analysis
- 11.7.1. Overview, Historic and Forecast Sales Analysis
- 11.7.2. Middle East & Africa by Segment Sales Analysis
- 11.7.3. Middle East & Africa by Country Sales Analysis
- 11.7.4. Saudi Arabia Sales Analysis
- 11.7.5. UAE Sales Analysis
- 11.7.6. Israel Sales Analysis
- 11.7.7. South Africa Sales Analysis
- 11.7.8. Rest Of Middle East And Africa Sales Analysis
12 . COMPETITIVE LANDSCAPE OF THE ARTIFICIAL INTELLIGENCE IN GENOMICS COMPANIES
- 12.1. Artificial Intelligence In Genomics Market Competition
- 12.2. Partnership/Collaboration/Agreement
- 12.3. Merger And Acquisitions
- 12.4. New Product Launch
- 12.5. Other Developments
13 . COMPANY PROFILES OF ARTIFICIAL INTELLIGENCE IN GENOMICS INDUSTRY
- 13.1. Company Share Analysis
- 13.2. Market Concentration Rate
- 13.3. IBM (US)
- 13.3.1. Company Overview
- 13.3.2. Company Revenue
- 13.3.3. Products
- 13.3.4. Recent Developments
- 13.4. Microsoft (US)
- 13.4.1. Company Overview
- 13.4.2. Company Revenue
- 13.4.3. Products
- 13.4.4. Recent Developments
- 13.5. NVIDIA Corporation (US)
- 13.5.1. Company Overview
- 13.5.2. Company Revenue
- 13.5.3. Products
- 13.5.4. Recent Developments
- 13.6. Deep Genomics (Canada)
- 13.6.1. Company Overview
- 13.6.2. Company Revenue
- 13.6.3. Products
- 13.6.4. Recent Developments
- 13.7. BenevolentAI (UK)
- 13.7.1. Company Overview
- 13.7.2. Company Revenue
- 13.7.3. Products
- 13.7.4. Recent Developments
- 13.8. Fabric Genomics Inc. (US)
- 13.8.1. Company Overview
- 13.8.2. Company Revenue
- 13.8.3. Products
- 13.8.4. Recent Developments
- 13.9. Verge Genomics (US)
- 13.9.1. Company Overview
- 13.9.2. Company Revenue
- 13.9.3. Products
- 13.9.4. Recent Developments
- 13.10. Freenome Holdings Inc. (US)
- 13.10.1. Company Overview
- 13.10.2. Company Revenue
- 13.10.3. Products
- 13.10.4. Recent Developments
- 13.11. MolecularMatch Inc. (US)
- 13.11.1. Company Overview
- 13.11.2. Company Revenue
- 13.11.3. Products
- 13.11.4. Recent Developments
- 13.12. Cambridge Cancer Genomics (UK)
- 13.12.1. Company Overview
- 13.12.2. Company Revenue
- 13.12.3. Products
- 13.12.4. Recent Developments
- 13.13. SOPHiA GENETICS (US)
- 13.13.1. Company Overview
- 13.13.2. Company Revenue
- 13.13.3. Products
- 13.13.4. Recent Developments
- 13.14. Data4Cure Inc. (US)
- 13.14.1. Company Overview
- 13.14.2. Company Revenue
- 13.14.3. Products
- 13.14.4. Recent Developments
- 13.15. PrecisionLife Ltd (UK)
- 13.15.1. Company Overview
- 13.15.2. Company Revenue
- 13.15.3. Products
- 13.15.4. Recent Developments
- 13.16. Genoox Ltd. (US)
- 13.16.1. Company Overview
- 13.16.2. Company Revenue
- 13.16.3. Products
- 13.16.4. Recent Developments
- 13.17. Lifebit (UK)
- 13.17.1. Company Overview
- 13.17.2. Company Revenue
- 13.17.3. Products
- 13.17.4. Recent Developments
- 13.18. Diploid (Belgium)
- 13.18.1. Company Overview
- 13.18.2. Company Revenue
- 13.18.3. Products
- 13.18.4. Recent Developments
- 13.19. FDNA Inc. (US)
- 13.19.1. Company Overview
- 13.19.2. Company Revenue
- 13.19.3. Products
- 13.19.4. Recent Developments
- 13.20. DNAnexus Inc. (US)
- 13.20.1. Company Overview
- 13.20.2. Company Revenue
- 13.20.3. Products
- 13.20.4. Recent Developments
- 13.21. Empiric Logic (Ireland)
- 13.21.1. Company Overview
- 13.21.2. Company Revenue
- 13.21.3. Products
- 13.21.4. Recent Developments
- 13.22. Engine Biosciences Pte. Ltd. (US)
- 13.22.1. Company Overview
- 13.22.2. Company Revenue
- 13.22.3. Products
- 13.22.4. Recent Developments
Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies